AstraZeneca and its global biologics research and development arm, MedImmune, will present the latest research from the Company’s Cardiovascular and Metabolic Diseases (CVMD) therapy area, including for Farxiga (dapagliflozin) and Bydureon (exenatide extended-release), with more than 50 abstracts at the American Diabetes Association’s (ADA) 77th Scientific Sessions in San Diego, USA, 9-13 June 2017.

Ludovic Helfgott, vice president, CVMD, said: “Science points to the need to move beyond lowering blood sugar to treat patients with type-2 diabetes holistically and earlier in their disease progression. Through investment in rigorous clinical and real-world evidence studies in large and diverse patient populations, we are committed to advancing scientific understanding of the connections between these highly-prevalent cardiovascular and metabolic diseases and helping to enhance clinical practice to improve the lives of patients.”

Highlights include a comprehensive updated safety analysis of dapagliflozin and three additional analyses from the landmark CVD-REAL real-world evidence study, including CV data for dapagliflozin, evaluating the risk of hospitalisation for kidney disease and heart failure (HF), as well as all-cause mortality, compared to DPP-4 inhibitors, a commonly-used treatment for type-2 diabetes (T2D). Additionally, a late-breaking oral presentation will explore the rates of HF and death in patients with T2D, both with and without cardiovascular disease, receiving treatment with SGLT-2 inhibitors (SGLT-2i) versus other T2D medicines.

Also presented will be the baseline characteristics and trial design of DECLARE, the largest cardiovascular outcomes trial in the SGLT-2i class. Both CVD-REAL and DECLARE are part of the extensive DapaCare programme for dapagliflozin, which involves patients with and without T2D to generate data across established CV disease, CV risk factors and varying stages of renal disease, providing healthcare providers with evidence needed to improve patient care.

AstraZeneca will also present analyses from DURATION-8, evaluating the investigational use of exenatide extended-release in combination with dapagliflozin, as well as primary data from DURATION-7, examining exenatide extended-release in combination with basal insulin.